- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00143780
Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination
Immunogenicity of Pneumococcal Conjugate Vaccine in Adult Allogeneic Bone Marrow Transplant Recipients - Randomized Controlled Trial of Pre-Transplant Donor Immunization
Study Overview
Status
Conditions
Detailed Description
This is a randomized controlled trial designed to assess the immunogenicity of the new pneumococcal conjugate vaccine in a cohort of allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. This will be done by using an approach of pre-transplant donor immunization with post-transplant recipient immunization. Response will be compared with the standard 23-valent polysaccharide vaccine. It is hypothesized that the conjugate vaccine will provide an enhanced response in this group of immunosuppressed individuals who respond poorly to standard polysaccharide vaccines.
Specific objectives of this study are:
- To determine the antibody response to both vaccines via a measurement of total antibody response and by the opsonophagocytic assay. This assay has the advantage of assessing if patient antibody responses represent truly functional antibodies that display opsonic activity against pneumococcus and is likely better correlated with protective efficacy.
- To determine any acute adverse reactions of the conjugate vaccine in this population. Results of this trial will help lay the foundation for the development of a rationale and optimal pneumococcal vaccination strategy that would prevent significant morbidity in this patient population.
We hypothesize that pneumococcal conjugate vaccine, due to its T-cell dependent response will have greater immunogenicity and protective effect in an allo-HSCT population by using a donor immunization strategy.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Recipient - Adult male or female marrow recipients who fulfill the following criteria will be eligible for the study: a) Will undergo allogeneic-HSCT in 2-3 weeks.
b) No splenectomy c) Not currently receiving IVIG d) Able to provide written informed consent and comply with study protocol e) Age > 16
Donor - Adult male or female marrow donors who fulfill the following criteria will be eligible for the study:
- Recipient of donor marrow agrees to participate in study.
- No prior pneumococcal vaccination within the last 5 years
- Not on immunosuppressive medication (eg., corticosteroids)
- No history of immunosuppressive condition that may potentially impair vaccine response eg, systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis
- No splenectomy
- Able to provide written informed consent and comply with study protocol
- Age > 16
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Immunogenicity of two vaccines via a determination of serotype specific capsular antibody formation and functional antibody formation from donor and recipient serum.
|
Secondary Outcome Measures
Outcome Measure |
---|
All patients will be called by telephone 24 hours after receiving vaccine to determine if any acute adverse events occurred. Any occurance of pneumococcal disease in recipients for one year post-transplant during the study period will be recorded.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Deepali Kumar, BSc, MSc, MD, FRCP(C), University Health Network, Toronto
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 02-0182-C
- P.S.I. Grant No. 02-67
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Marrow Transplant
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Duke UniversityCompletedBone Marrow Transplant
-
University of Colorado, DenverGlaxoSmithKlineRecruitingStem Cell Transplant | Bone Marrow TransplantUnited States
-
Arizona State UniversityMayo ClinicCompleted
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedBone Marrow TransplantUnited States
-
Mayo ClinicCompletedStem Cell Transplant | Immunosuppression | Bone Marrow TransplantUnited States
-
Stanford UniversityNational Institutes of Health (NIH)WithdrawnBone Marrow Transplant | Hematopoietic Stem Cell Transplant
-
Nationwide Children's HospitalColumbia UniversityNot yet recruiting
-
University of Colorado, DenverReimagine CareCompletedBone Marrow TransplantUnited States
-
Stanford UniversityCompletedBone Marrow Transplant | Advance DirectivesUnited States
-
St. Jude Children's Research HospitalCompletedStem Cell Transplant | Bone MarrowUnited States, Canada
Clinical Trials on The polysaccharide vaccine used is Pneumovax (Merck vaccines)
-
University Health Network, TorontoUnknown
-
Helsinki University Central HospitalCompleted
-
Sheba Medical CenterUnknownAtaxia TelangiectasiaIsrael
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI)CompletedPulmonary Disease, Chronic ObstructiveUnited States
-
Merck Sharp & Dohme LLCCompletedHerpes Zoster | Pneumococcal Infection
-
Emory UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Medical University of South CarolinaCompletedAging | HIV LipodystrophyUnited States
-
Seema BhatRecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
PATHCompleted
-
University of UtahNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States